Abstract
We present a case report of a neonate receiving raltegravir-based postnatal HIV prophylaxis after in utero dolutegravir exposure. High levels of raltegravir and dolutegravir can potentially cause bilirubin toxicity as they compete for albumin binding and follow the same metabolic pathway through UGT1A1. This case suggests delaying initiation of raltegravir-based postnatal prophylaxis by 24-48 hours after in utero dolutegravir exposure.
Author supplied keywords
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Cite
CITATION STYLE
Jacobs, T. G., van Aerde, K. J., Colbers, A., & Burger, D. M. (2022). Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure. Pediatric Infectious Disease Journal, 41(2), 131–132. https://doi.org/10.1097/INF.0000000000003364
Readers' Seniority
Readers' Discipline
